Frozen Shoulder. Adhesive capsulitis of shoulder
Conditions
Interventions
Intervention 1: Daily intake of one capsule containing curcumin-piperine (with 500 mg of curcumin extract and 5 mg of piperine) alongside manual therapy (3 sessions per week) for 14 days. Manual Thera
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Agreement for participation in the study Age of 20 to 65 years old Diagnosis of frozen shoulder syndrome patients by an orthopedic specialist Duration of symptoms between 1 and 12 months
Exclusion criteria
Exclusion criteria: Unwillingness or inability to provide informed consent or adhere to the study protocol. Consumption of less than 80% of the prescribed supplement/placebo (verified by pill count). Voluntary withdrawal from the study or being lost to follow-up Occurrence of any allergic reaction or serious adverse event related to manual therapy or the supplement that makes continuation unsafe. Significant worsening of pain or functional limitation requiring additional intervention (e.g., corticosteroid injection or surgery) Systemic Inflammatory Diseases: Rheumatoid arthritis, ankylosing spondylitis, lupus, active gout, or other inflammatory arthropathies. Neuromuscular Disorders: Severe peripheral neuropathy, cervical radiculopathy, thoracic outlet syndrome, or stroke with residual upper limb impairment affecting function. Severe Uncontrolled Systemic Diseases: Renal or hepatic failure, active malignancy, bleeding disorders, active peptic ulcer disease, inflammatory bowel disease, cholelithiasis, or bile duct obstruction. Use of any supplement containing curcumin, turmeric, or other potent herbal anti-inflammatory agents within the past 4 weeks. Smoking Current participation in any other clinical trial. Other Shoulder Pathologies:* Diagnosis of impingement syndrome or full-thickness rotator cuff tear.* Symptomatic glenohumeral osteoarthritis.* Shoulder instability, prior dislocation, or history of surgery on the affected shoulder.* Cervical radiculopathy or other neurogenic causes of shoulder pain (confirmed by neurological examination).* Secondary frozen shoulder (due to diabetes, thyroid disorder, stroke, Parkinson's disease, trauma).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of shoulder function, range of motion, pain, and disability in patients with frozen shoulder. Timepoint: At baseline and after 14 days. Method of measurement: Questionnaire.;Serum level of High sensitive C reactive protein. Timepoint: At baseline and after 14 days. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;Total antioxidant capacity. Timepoint: At baseline and after 14 days. Method of measurement: Biochemical kit of KiaZist Co.;Total oxidant status. Timepoint: At baseline and after 14 days. Method of measurement: Biochemical kit of KiaZist Co.;Muscle nerve band. Timepoint: At baseline and after 14 days. Method of measurement: Electromyography.;Malondialdehyde. Timepoint: At baseline and after 14 days. Method of measurement: Biochemical kit of KiaZist Co.;Serum concentration of glutathione. Timepoint: At baseline and after 14 days. Method of measurement: Biochemical kit of KiaZist Co.;Superoxide dismutase activity. Timepoint: At baseline and after 14 days. Method of measurement: Biochemical kit of KiaZist Co.;Serum level of vascular cell adhesion molecule-1. Timepoint: At baseline and after 14 days. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;Erythrocyte sedimentation rate (ESR). Timepoint: At baseline and after 14 days. Method of measurement: Biochemical kit of KiaZist Co.;Serum level of IL-6. Timepoint: At baseline and after 14 days. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;Serum level of TNF-a. Timepoint: At baseline and after 14 days. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;Serum level of TGF. Timepoint: At baseline and after 14 days. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;Serum level of IL-1ß. Timepoint: At baseline and after 14 days. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.;Serum level of IL-8. Timepoint: At baseline and after 14 days. Method of measurement: Enzyme-linked im | — |
Secondary
| Measure | Time frame |
|---|---|
| The average level of (total cholesterol, HDL, LDL, TG) in the intervention and control groups. Timepoint: Before and after intervention. Method of measurement: Kiazist biochemical kit.;The mean level of fasting blood sugar (FBS) among the intervention and control groups. Timepoint: Before and after intervention. Method of measurement: Kiazist biochemical kit.;Quality of Life. Timepoint: Before and after intervention. Method of measurement: Quality of life questionnaire.;Assessment of mental health status. Timepoint: Before and after intervention. Method of measurement: Depression, Anxiety, and Stress Scale (DASS-21). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Gholamreza Askari
Esfahan University of Medical Sciences
Outcome results
None listed